Price T Rowe Associates Inc Tarsus Pharmaceuticals, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TARS
# of Institutions
166Shares Held
39.5MCall Options Held
190KPut Options Held
92.9K-
Rtw Investments, LP New York, NY3.27MShares$90.2 Million1.91% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.86MShares$78.9 Million3.9% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$73.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.4MShares$66.1 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$62.1 Million9.98% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $734M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...